- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Marksans Pharma is engaged in the Business of Formulation of pharmaceutical products.
Marksans Pharma will participate in a physical group meet at the Ashwamedh - Elara India Dialogue 2026 on September 02, 2026, at Hyatt, Santacruz East, Mumbai. The company confirmed that no unpublished price sensitive information will be shared during the interactions.
Marksans Pharma posted a stellar Q1 FY27: Revenue hit INR 841 Cr (+35.6% YoY), with highest-ever EBITDA of INR 213 Cr (+112.8% YoY) and PAT of INR 159 Cr (+173.9% YoY). Gross margin reached 59.1%, EBITDA margin 25.3%. Cash balance surpassed INR 1,000 Cr. Europe was a key driver, growing...